Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study

Carlos Escriva-Aranda, Eduardo Giner-Moreno, Emilio Soria Hernández, Josep Esteve Gallego, Elisa Gómez Roch, Patricia Capdevila, Cristobal Carrasco Picazo, Alba Ortiz Gracia, Daniel Vidal Jiménez, Jorge Aparicio, Robert Díaz Beveridge

Therapeutic Advances in Medical Oncology

Published online on June 18, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) are the main first-line regimens for advanced pancreatic adenocarcinoma. No randomized clinical trials have directly compared their efficacy, and real-world data remain limited....